Skip to content

ACRV - Acrivon Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchA

Acrivon Therapeutics, Inc. Common Stock

ACRV · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

A

ACRVAcrivon Therapeutics, Inc. Common Stock

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $3.56
52-wk low: $1.27
Prev close: $2.41
Mkt cap: $102.4M
Beta: 1.86
P/B: 1.0x

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$4.4M

JS
Jim Simons
Q2 2026 13F
$1.4M
position
TS
Two Sigma
Q2 2026 13F

Earnings

Reported Aug 12, 2026

Earnings came in 12.2% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $102M

Valuation

P/B1.01

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: ACRV
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $102.42M
Beta: 1.86

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Profit margin

+0.0%

Op margin

+0.0%

ROE

-64.6%

$1.1M

position

MW

Marshall Wace

Q2 2026 13F

$947K

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for ACRV

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.43+12.2%

-$0.49 expected

Next report

What the street expects next

EPS expected

-$0.45

-$0.48 to -$0.43

Revenue expected

$0.00

8 analysts

Last 30 days

2up3down

Analysts cutting estimates

Estimate drift

+0.07

Change in 30 days

-64.6%

ROA-38.0%

Growth

Beta1.86